[go: up one dir, main page]

WO2022103817A3 - Molécules d'arn destinées à être utilisées pour inhiber la production de protéines du sars-cov-2 - Google Patents

Molécules d'arn destinées à être utilisées pour inhiber la production de protéines du sars-cov-2 Download PDF

Info

Publication number
WO2022103817A3
WO2022103817A3 PCT/US2021/058753 US2021058753W WO2022103817A3 WO 2022103817 A3 WO2022103817 A3 WO 2022103817A3 US 2021058753 W US2021058753 W US 2021058753W WO 2022103817 A3 WO2022103817 A3 WO 2022103817A3
Authority
WO
WIPO (PCT)
Prior art keywords
seq
nucleotide sequence
cov
protein production
rna molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/058753
Other languages
English (en)
Other versions
WO2022103817A2 (fr
Inventor
Gary Ian GALLICANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of WO2022103817A2 publication Critical patent/WO2022103817A2/fr
Publication of WO2022103817A3 publication Critical patent/WO2022103817A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes d'inhibition ou de prévention de la production de la production de protéines du SARS-CoV-2 dans des cellules. Lesdites méthodes comprennent l'adminitration à un sujet d'un ARNsi comprenant un brin sens comprenant une séquence nucléotidique de SEQ ID NO : 1 et un brin antisens comprenant une séquence nucléotidique de SEQ ID NO : 2 ; ou comprenant un brin sens comprenant une séquence nucléotidique de SEQ ID NO : 3 et un brin antisens comprenant une séquence nucléotidique de SEQ ID NO : 4 ; ou comprenant un brin sens comprenant une séquence nucléotidique de SEQ ID NO : 13 et un brin antisens comprenant une séquence nucléotidique de SEQ ID NO : 14. En variante, lesdites méthodes comprennent l'administration d'une molécule de micro-ARN comprenant une séquence nucléotidique de SEQ ID NO : 5, ou comprenant une séquence nucléotidique de SEQ ID NO : 6.
PCT/US2021/058753 2020-11-11 2021-11-10 Molécules d'arn destinées à être utilisées pour inhiber la production de protéines du sars-cov-2 Ceased WO2022103817A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063112156P 2020-11-11 2020-11-11
US63/112,156 2020-11-11

Publications (2)

Publication Number Publication Date
WO2022103817A2 WO2022103817A2 (fr) 2022-05-19
WO2022103817A3 true WO2022103817A3 (fr) 2022-06-09

Family

ID=81602672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/058753 Ceased WO2022103817A2 (fr) 2020-11-11 2021-11-10 Molécules d'arn destinées à être utilisées pour inhiber la production de protéines du sars-cov-2

Country Status (1)

Country Link
WO (1) WO2022103817A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258611A1 (en) * 2003-05-19 2006-11-16 University Of Hong Kong Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
CN111139241A (zh) * 2020-04-03 2020-05-12 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用
RU2733361C1 (ru) * 2020-07-14 2020-10-01 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258611A1 (en) * 2003-05-19 2006-11-16 University Of Hong Kong Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
CN111139241A (zh) * 2020-04-03 2020-05-12 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用
RU2733361C1 (ru) * 2020-07-14 2020-10-01 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией

Also Published As

Publication number Publication date
WO2022103817A2 (fr) 2022-05-19

Similar Documents

Publication Publication Date Title
EP4527459A3 (fr) Acide nucléique, composition et conjugué contenant un acide nucléique, procédé de préparation et utilisation associés
EP3236976B1 (fr) Agents d'interférence arn utilisables en vue de la modulation du gène p21
AU2015355546B2 (en) Guide RNA with chemical modifications
AU2005201044B2 (en) Method and medicament for inhibiting the expression of a defined gene
US8513401B2 (en) Double stranded nucleic acid targeting low copy promoter-specific RNA
WO2020198509A3 (fr) Oligonucléotides modifiés à stabilité accrue
EP4455285A3 (fr) Acide nucléique, composition et conjugué le comprenant, et procédé de préparation et utilisation de ceux-ci
WO2020205605A3 (fr) Modulation, à base d'oligonucléotides, de c9orf72
CN110959042B (zh) 一种新型小激活rna
AU2008339215A8 (en) Novel siRNA structure for minimizing off-target effects and relaxing saturation of RNAi machinery and the use thereof
SG170780A1 (en) Compositions and methods for inhibiting expression of eg5 gene
WO2006119266A3 (fr) Micro-arn humains et procedes d'inhibition de ceux-ci
IL151928A (en) Preparation, pharmaceutical preparations and uses of rna-specific rna disorder mediators
EP2021507A4 (fr) Compositions et procédés d'inhibition de l'expression du gène pcsk9
PL1687435T3 (pl) Odporność na owady z użyciem hamowania ekspresji genów
WO2006135436A3 (fr) Inhibition de l'expression genique et ses usages therapeutiques
JP7566741B2 (ja) プログラム可能なｓｉＲＮＡ及びその使用
SG165394A1 (en) Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
Moccia et al. Insights on chiral, backbone modified peptide nucleic acids: properties and biological activity
NO20083089L (no) Antimyosin Va siRNA og huddepigmentering
WO2007137156A8 (fr) Modulation d'aha par l'arn et utilisateurs thérapeutiques de celle-ci
WO2008036638A3 (fr) MODULATION PAR L'ARNi DE GÈNE SCAP ET UTILISATIONS THÉRAPEUTIQUES
NZ604094A (en) Double stranded rna compounds to rhoa and use thereof
WO2013065791A1 (fr) Molécule d'acide nucléique double brin utilisable à des fins de régulation de l'expression génique
WO2022103817A3 (fr) Molécules d'arn destinées à être utilisées pour inhiber la production de protéines du sars-cov-2

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE